Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults
Open accessPublished version of a preprint
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background: Irritable bowel syndrome (IBS) with diarrhoea (IBS-D) is a common and chronic condition that can significantly impair quality of life. The emergence of new drugs for IBS-D has been slow and there is a need for new treatments, including drug-free treatments, which are easy to use and suitable for different patient groups. Currently available drug-free treatments include Enterosgel®, an intestinal adsorbent approved for use in IBS-D and acute diarrhoea and available over-the-counter in the UK and 30 countries worldwide. The aim of this randomised, double-blind, placebo-controlled, multi-centre study is to test the efficacy and safety of Enterosgel® compared to placebo in symptomatic treatment in IBS-D. Methods/design: We will recruit 430 participants with IBS-D from approximately 30 primary and secondary care sites in England. Participants meeting the required abdominal pain and stool consistency criteria over a 2-week screening period will be randomly allocated to receive blinded treatment (Enterosgel® or placebo) for 8 weeks. This will be followed by an 8-week open-label treatment phase with Enterosgel®. Participants will be allowed to adjust their daily dosage during both phases based on their symptoms. Participants will then return to standard care and those who responded to treatment will receive a follow-up call 8 weeks later. Co-medication with loperamide will be permitted and use recorded. The primary outcome measure is the percentage of participants defined as responders for abdominal pain and stool consistency during at least 4 weeks in the 8-week blinded phase. Secondary outcome measures include stool frequency, stool consistency, abdominal pain, bloating, urgency, adequate relief, questionnaire scores and rescue medication use. Exploratory outcomes will be assessed in subsets of participants including qualitative and quantitative data on faecal microorganisms and biomarkers and gut-related measurements from magnetic resonance imaging data. Discussion: This is the first large scale randomised controlled trial investigating Enterosgel® in IBS-D. A study design with blinded phase followed by an open-label phase was chosen to encourage participation and study completion. Demonstrating that Enterosgel® is effective and safe in IBS-D could encourage adoption by patients and healthcare professionals and foster future clinical trials assessing its use in related conditions. Trial registration: ISRCTN17149988 . Prospectively registered on 14 November 2017.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IBS research is leading the way in this regard with the first UK interventional virtual trial being conducted in IBS, demonstrating that virtual recruitment methods outperform site-dependent recruitment significantly.295 299”
From British Society of Gastroenterology guidelines on the management of irritable bowel syndrome (2021) · cites this paper as [295]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
Irritable Bowel Syndrome: A Clinical Review
Chey, W. D., Kurlander, J., & Eswaran, S. (2015) · JAMA · doi:10.1001/jama.2015.0954 · Cited by 1,081
The epidemiology of irritable bowel syndrome
Card, T., Canavan, C., & West, J. (2014) · Clinical Epidemiology · doi:10.2147/clep.s40245 · Cited by 889 · cited 2×
“Internationally, the overall prevalence of IBS in women is 67% higher than in men, although there are differences in the sex-specific prevalence between geographic regions [9].”
BackgroundGuidelines on the irritable bowel syndrome: mechanisms and practical management
Spiller, R., Aziz, Q., Creed, F., Emmanuel, A., Houghton, L., Hungin, P., Jones, R., Kumar, D., Rubin, G., Trudgill, N., et al. (2007) · Gut · doi:10.1136/gut.2007.119446 · Cited by 818
Self-citationDevelopment and Validation of the Rome IV Diagnostic Questionnaire for Adults
Palsson, O. S., Whitehead, W. E., van Tilburg, M. A. L., Chang, L., Chey, W., Crowell, M. D., Keefer, L., Lembo, A. J., Parkman, H. P., Rao, S. S. C., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.014 · Cited by 719
Self-citationPathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions
Öhman, L., & Simrén, M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.4 · Cited by 617
Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine
Saha, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i22.6759 · Cited by 500
Liu, H.-N., Wu, H., Chen, Y.-Z., Chen, Y.-J., Shen, X.-Z., & Liu, T.-T. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.01.142 · Cited by 254
Research works printed but not linked: 5
- World Gastroenterology Organisation. Global Guidelines. Updated September 2015. Irritable bowel syndrome: a global perspective. 2015. http://www.worldgastroenterology.org/guidelines/global-guidelines/irritable-bowel-syndrome-ibs. Accessed 13 Mar 2019.
- International Foundation for Functional Gastrointestinal Disorders. IBS in the real world survey. Summary findings. 2002. https://www.iffgd.org/images/pdfs/IBSRealWorld.pdf. Accessed 13 Mar 2019.
- Leonard AJD-LM, Allen A. Pepsin damage in rat stomach in vivo: effect of smectite and dimethyl prostaglandin E2. Gastroenterology. 1993;104:A132.
- Tkachenko EIAE, Skazyvaeva EV, Ivanov SV, Pushklna AV, Lapinskii IV. Efficiency and safety of Enterosgel (polymethylsiloxane polyhydrate) in the treatment of irritable bowel syndrome. Minerva Gastroenterol Dietol. 2015;61(N2):1–5.
- Pavlov AIFZV. Tactics of management of diarrhoea of non-infectious genesis in hospital (in Russian). Military Med J. 2018;6:49–54.
Cited by
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
Self-citationGutiérrez, Á. M., Frazar, E. M., Klaus, M. V. X., Paul, P., & Hilt, J. Z. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101820 · Cited by 153
Howell, C. A., Kemppinen, A., Allgar, V. L., Dodd, M., Knowles, C. H., McLaughlin, J. T., Pandya, P., Whorwell, P. J., Markaryan, E., & Yiannakou, Y. (2022) · Gut · doi:10.1136/gutjnl-2022-327293 · Cited by 38
“13 The study was designed in line with FDA guidance for clinical trials in IBS, 14 which allows direct comparison with other products.”
Self-citationMousavi, T., Nikfar, S., & Abdollahi, M. R. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1767067 · Cited by 32
The future of clinical trials—is it virtual?
Ng, C. E., Bowman, S., Ling, J., Bagshaw, R., Birt, A., & Yiannakou, Y. (2023) · British Medical Bulletin · doi:10.1093/bmb/ldad022 · Cited by 26
Self-citation
Metadata
- Authors
- Kemppinen, A., Howell, C., Allgar, V., Dodd, M., Gregson, J., Knowles, C., McLaughlin, J., Pandya, P., Whorwell, P., Markaryan, E., & Yiannakou, Y.
- Affiliations
- Enteromed (United Kingdom) (GB)
- University of York (GB)
- London School of Hygiene & Tropical Medicine (GB)
- Queen Mary University of London (GB)
- Salford Royal NHS Foundation Trust (GB)
- University of Manchester (GB)
- County Durham and Darlington NHS Foundation Trust (GB)
- Corresponding author
- Kemppinen, Anu
- ORCID
- Venue
- Trials
- Published
- 2020-01-30
- Volume
- 21
- Issue
- 1
- Pages
- 122-122
- ISSN
- 1745-6215 (ISSN-L)
- PMC
- PMC6993329
- OpenAlex
- W3004297104
- Cited by
- 14
- References
- 28
- Citations by year
- 2026: 1 · 2025: 3 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 1
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Trials (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- PEARL (University of Plymouth) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion, other-oa)
- Funders
- Bioline Products s.r.o (n/a)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- irritable bowel syndrome with diarrhea, Enterosgel, drug-free treatment, abdominal pain, stool consistency, stool frequency, bloating, gut microbiota biomarkers, treatment efficacy and safety
- MeSH terms
- Adult, Diarrhea, Double-Blind Method, Drug Carriers, Female, Gastrointestinal Agents, Humans, Intestinal Absorption, Male, Surveys and Questionnaires, Silicones, Multicenter Studies as Topic, Abdominal Pain, Randomized Controlled Trials as Topic, Sorption Detoxification, Outcome Assessment, Health Care, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. https://app.cochat.ai/papers/10.1186/s13063-020-4069-x
- The paper
- Kemppinen, A., Howell, C., Allgar, V., Dodd, M., Gregson, J., Knowles, C., McLaughlin, J., Pandya, P., Whorwell, P., Markaryan, E., & Yiannakou, Y. (2020). Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. Trials. https://doi.org/10.1186/s13063-020-4069-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

